Robert W. Baird set a $104.00 target price on HCA Healthcare (NYSE:HCA) in a report released on Friday morning. The firm currently has a buy rating on the stock.
Several other research firms have also commented on HCA. Zacks Investment Research upgraded shares of HCA Healthcare from a strong sell rating to a hold rating in a research note on Tuesday, December 19th. Piper Jaffray Companies lowered shares of HCA Healthcare from an overweight rating to a neutral rating and set a $81.00 price objective for the company. in a research note on Wednesday, January 3rd. Goldman Sachs Group initiated coverage on shares of HCA Healthcare in a research note on Wednesday, January 3rd. They issued a neutral rating for the company. Credit Suisse Group restated an outperform rating and set a $25.00 price target on shares of HCA Healthcare in a research note on Tuesday, December 26th. Finally, Morgan Stanley lowered shares of HCA Healthcare from an equal weight rating to an underweight rating and set a $85.00 price target for the company. in a research note on Wednesday, December 20th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and eighteen have assigned a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $88.70.
HCA Healthcare (HCA) traded up $1.83 during trading hours on Friday, reaching $88.80. 1,871,300 shares of the company’s stock traded hands, compared to its average volume of 2,087,933. The company has a debt-to-equity ratio of -6.46, a quick ratio of 1.41 and a current ratio of 1.68. The stock has a market cap of $32,170.00, a price-to-earnings ratio of 12.63, a price-to-earnings-growth ratio of 1.19 and a beta of 0.55. HCA Healthcare has a 52-week low of $71.18 and a 52-week high of $91.03.
HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Tuesday, October 31st. The company reported $1.21 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.21. The firm had revenue of $10.70 billion during the quarter, compared to analyst estimates of $10.70 billion. HCA Healthcare had a net margin of 6.13% and a negative return on equity of 47.16%. The company’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter last year, the business posted $1.45 EPS. analysts expect that HCA Healthcare will post 6.56 earnings per share for the current year.
In related news, insider Michael S. Cuffe sold 2,400 shares of HCA Healthcare stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $86.63, for a total value of $207,912.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Victor L. Campbell sold 8,000 shares of HCA Healthcare stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $75.82, for a total transaction of $606,560.00. Following the completion of the transaction, the senior vice president now owns 127,275 shares of the company’s stock, valued at $9,649,990.50. The disclosure for this sale can be found here. Insiders sold a total of 20,550 shares of company stock valued at $1,606,172 over the last quarter. 2.90% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in HCA. Commonwealth Bank of Australia grew its stake in HCA Healthcare by 14.7% in the 2nd quarter. Commonwealth Bank of Australia now owns 4,281 shares of the company’s stock valued at $372,000 after buying an additional 548 shares in the last quarter. Dai Ichi Life Insurance Company Ltd boosted its holdings in HCA Healthcare by 1.2% in the 2nd quarter. Dai Ichi Life Insurance Company Ltd now owns 20,577 shares of the company’s stock valued at $1,794,000 after purchasing an additional 236 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in HCA Healthcare by 14.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,163 shares of the company’s stock valued at $101,000 after purchasing an additional 143 shares during the period. Ameriprise Financial Inc. boosted its holdings in HCA Healthcare by 2.8% in the 2nd quarter. Ameriprise Financial Inc. now owns 549,314 shares of the company’s stock valued at $47,901,000 after purchasing an additional 14,912 shares during the period. Finally, Amalgamated Bank boosted its holdings in HCA Healthcare by 47.9% in the 2nd quarter. Amalgamated Bank now owns 33,229 shares of the company’s stock valued at $2,898,000 after purchasing an additional 10,756 shares during the period. Institutional investors and hedge funds own 75.35% of the company’s stock.
WARNING: “Robert W. Baird Analysts Give HCA Healthcare (HCA) a $104.00 Price Target” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/16/robert-w-baird-analysts-give-hca-healthcare-hca-a-104-00-price-target.html.
HCA Healthcare Company Profile
HCA Healthcare, Inc, formerly HCA Holdings, Inc, is a holding company. The Company, through its subsidiaries, owns and operates hospitals and related healthcare entities. As of December 31, 2016, the Company operated in two geographically organized groups, including the National and American Groups. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, Indiana, northern Kentucky, Nevada, New Hampshire, South Carolina, Utah and Virginia.
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.